This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.
Earnings Preview: Bio-Rad Laboratories (BIO) Q2 Earnings Expected to Decline
by Zacks Equity Research
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms
by Zacks Equity Research
BIO surges 4% as the Stilla acquisition fuels the launch of four ddPCR systems, expanding to 400K+ assay offerings.
New Strong Sell Stocks for July 10th
by Zacks Equity Research
BIO, DECK and ELUXY have been added to the Zacks Rank #5 (Strong Sell) List on July 10, 2025.
Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?
by Moumi Mondal
HOLX lifts margins despite tariffs and weak China sales, leaning on diagnostics strength and high-margin buys.
Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends
by Zacks Equity Research
Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket
by Zacks Equity Research
Bio-Rad witnesses first-quarter top-line decline in its Life Science segment, primarily due to challenges in the academic research market.
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 46.82% and 0.05%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
by Zacks Equity Research
BIO continues to attract investors' attention due to its robust performance in the ddPCR platform.
Bio-Techne Opens New Customer Experience Centre in Germany
by Zacks Equity Research
TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany.
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate
by Zacks Equity Research
Charles River and Valo Health identify a potential therapeutic for lupus using their combined offering, Logica.
Bio-Rad (BIO) International Revenue Performance Explored
by Zacks Equity Research
Review Bio-Rad's (BIO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
HSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket
by Zacks Equity Research
Henry Schein's fourth-quarter results reflect stable dental and medical end-markets.
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat
by Zacks Equity Research
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips
by Zacks Equity Research
GMED's fourth-quarter 2024 performance reflects strong synergies from the NuVasive merger.
EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y
by Zacks Equity Research
Exact Sciences' fourth-quarter 2024 performance benefits from the robust momentum in Cologuard adoption.
Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises
by Zacks Equity Research
Penumbra reports better-than-expected earnings and revenues in the fourth quarter of 2024.
Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles
by Zacks Equity Research
MDT delivers strong earnings in the fiscal 2025 third quarter, with significant improvements in both gross and operating margins.
BIO Stock Might Rise Following the Offer to Acquire Stilla
by Zacks Equity Research
Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket
by Zacks Equity Research
Bio-Rad witnesses growth across the Clinical Diagnostics segment in the fourth quarter, primarily driven by an increased demand for quality control and blood typing products.
Bruker Q4 Earnings & Revenues Surpass Estimates, Stock Falls
by Zacks Equity Research
Bruker delivers better-than-expected earnings and revenues in the fourth quarter of 2024.
Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of -1.02% and 1.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise
by Zacks Equity Research
CVS tops earnings and revenue estimates in the fourth quarter of 2024 amid macroeconomic impacts in the Health Care Benefits arm.
Omnicell Q4 Earnings & Revenues Beat, Stock Up, Gross Margin Rises
by Zacks Equity Research
OMCL returns to year-over-year revenue growth in the fourth quarter of 2024.